China Drug Discovery Landscape
Interview with Helen Chen, Ph.D., Director and Partner, Head of China Life Sciences, L.E.K. Consulting, Shanghai
Part 1: China or not? The decision process
on June 16, 2010
"... it seems that every other week there is a new announcement of a Big Pharma R&D center expansion, another CRO getting funding, or a domestic Chinese company planning a U.S. clinical trial." In this interview at BioPacific 2010, where she presented an overview of the China drug discovery landscape, Helen Chen discussed the changing dynamics of China R&D, and shared some key learning as an active participant in the arena advising Western and Chinese domestic clients.
Tags: CABS, BioPacific 2010, Helen Chen, LEK, China, CRO, pre-clinical, profiling